Onesource Specialty Pharma logo

Onesource Specialty Pharma financials: balance sheet, profit and loss, cash flow

NSE: ONESOURCEBSE: 544292Pharmaceuticals & BiotechnologySmall Cap

Onesource Specialty Pharma Limited · Face value ₹1 · Listed Jan 2025
Last close ₹1,569.60down ₹8.00 (0.51%)BSE ₹1,569.65

Share price at the NSE close on 29 Oct 2026. Previous close ₹1,577.60.

29 Oct: open ₹1,585.00, high ₹1,597.60, low ₹1,564.00

52-week range of traded prices to 29 Oct 2026
₹1,057.00Low, 30 Jan 2026₹1,925.00High, 3 Nov 2025
Market cap
₹17,999 Cr373rd largest listed
P/E
Lossover the last 12 months
P/B
3.04
Dividend yield
Nonein the last 12 months
ROE
0.0%
ROE without one-offs
0.2%
ROCE
1.5%
Debt to equity
0.25
Volume, NSE
7,36,95662.9% delivered

Onesource Specialty Pharma's financial statements for the 2 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

2 years at a glance

₹ crore, years to March.Onesource Specialty Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
1,445−18772Mar 251,422−741,276Mar 26
Peak revenue ₹1,445 Cr, year to Mar 2025; lowest ₹1,422 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin
32.3%−5.2%32.3%21.4%−1.2%−5.2%Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,422
  2. Materials and goods−445
  3. Employee costs−242
  4. Other expenses−430
  5. Operating profit304
  6. Depreciation−279
  7. Other income+15
  8. One-off items−9.9
  9. Finance costs−122
  10. Profit before tax−92
  11. Tax+18
  12. Net profit−74

What the company owns

  • Plant, investments and other assets₹6,978 Cr
  • Receivables₹690 Cr
  • Inventory₹439 Cr
  • Cash and bank₹98 Cr
  • Current investments₹5 Cr

What pays for it: net worth and liabilities

  • Net worth₹5,831 Cr
  • Borrowings₹1,276 Cr
  • Other liabilities₹728 Cr
  • Owed to suppliers₹375 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Onesource Specialty Pharma quarterly results

₹ croreMar 2025Filed 5 MayMar 2026Filed 13 MaySep 2026Twelve monthsFiled 27 Oct
Revenue from operations1,4451,4221,684
9781,1171,288
Materials and goods bought435445530
Employee costs215242273
Other expenses328430484
Operating profit before depreciation467304396
Operating margin32.3%21.4%23.5%
Materials, % of revenue30.1%31.3%31.5%
Employee costs, % of revenue14.9%17.0%16.2%
Other expenses, % of revenue22.7%30.3%28.8%
Depreciation and amortisation274279288
Operating profit after depreciation19325108
Other income171511
Finance costs166122126
Profit before one-off items and tax44−82−7
One-off items−111−10−13
Profit before tax−67−92−20
−50−18−19
Profit from discontinued businesses−1––
Net profit−18−74−2
Other comprehensive income−31614
Total comprehensive income−21−5812
Net margin−1.2%−5.2%−0.1%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2025Filed 5 MayMar 2026Filed 13 MaySep 2026Half yearFiled 27 Oct
5,8815,8315,921
Share capital111111
Reserves5,8695,8205,909
7721,2761,484
1,1141,4421,664
5569371,002
Total assets7,5508,2108,586
6,4646,7846,889
1,0861,4261,697
Net debt4621,1731,445
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2025Filed 5 MayMar 2026Filed 13 MaySep 2026Half year
−229−19
−2917−17
−420−277−320
Receivables−257−190−361
Inventories44−281−7
Payables−118209166
Other working capital−89−15−118
Tax paid7−9−2
Capital spending0569171
Free cash flow−22−561−190
−201−495−128
1,987359125
Dividends paid000
Shares bought back000
Shares issued87660
Net change in cash1,765−127−21
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2025Filed 5 MayMar 2026Filed 13 May
Earnings per share−₹1.63−₹6.44
Diluted earnings per share−₹1.63−₹6.44
Book value per share₹513.90₹508.75
Shareholder yield−4.4%0.0%
Market cap at the year end (₹ crore)20,05216,882

Ratios

Consolidated, years to March.Onesource Specialty Pharma PE ratio and valuation

RatioMar 2025Filed 5 MayMar 2026Filed 13 May
Revenue growth–−1.6%
Operating profit growth–−34.8%
−0.3%−1.3%
–−1.0 pts
From the net margin–−1.0 pts
From asset turnover–0.1 pts
From borrowing–−0.1 pts
Return on capital employed2.9%0.4%
Interest cover1.20.2
Debt to equity0.130.22
Receivable days105177
Inventory days133360
Payable days147307
Cash conversion cycle, days91230
Working capital days54152
Asset turnover0.190.18
Assets per rupee of net worth1.281.35
Sales per rupee of plant1.611.54
Capital spending to depreciation0.002.04
Plant being built, % of plant in use6.7%33.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−0.9%
Cash from operations against operating profit
2.8%
Measure3 years
Return on equity, average−0.8%
Return on capital employed, average1.6%
Operating margin, average26.8%
Net margin, average−3.2%
Asset turnover, average0.19
Cash conversion cycle, days, average160
Interest cover, average0.7
Debt to equity, average0.18

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations9
Cash from investing−495
Cash from financing359
Capital spending569
Dividends paid0
Shares bought back0
Shares issued for cash6
Borrowings raised704
Borrowings repaid207

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.818.525.43
Beneish M-scorePublished threshold −1.78–−2.07
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–5.24
Receivables growth less revenue growthOur threshold 0 percentage points–67.29
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–175.50
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−0.56
Assets under construction, years of additionsOur threshold 2 years of additions–1.02
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
17 Aug 2026India Ratings and Research Private LimitedBank loan facilitiesIND A; IND A1New, NewPositive428.71
5 Mar 2026CARE Ratings LimitedFund-based - LT-Term loan / Working Capital FacilityWithdrawnReview, Other
5 Mar 2026CARE Ratings LimitedDebentures-Non Convertible DebenturesWithdrawnReview, Other
5 Mar 2026CARE Ratings LimitedFund-based/Non-fund-based-LT/STWithdrawnReview, Other
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.